Stay updated on Consolidation Pembrolizumab in Stage III NSCLC Clinical Trial
Sign up to get notified when there's something new on the Consolidation Pembrolizumab in Stage III NSCLC Clinical Trial page.

Latest updates to the Consolidation Pembrolizumab in Stage III NSCLC Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has undergone significant changes, including the removal of detailed trial information and eligibility criteria for a Phase II trial of pembrolizumab in NSCLC, while adding references to collaborators and a new revision number.SummaryDifference35%
- Check29 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check87 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check94 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
Stay in the know with updates to Consolidation Pembrolizumab in Stage III NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Consolidation Pembrolizumab in Stage III NSCLC Clinical Trial page.